APA (7th ed.) Citation

R, S., L, d. M. d. J., & C, C. (2026). Response to the letter of Peng Bai and Jun Zhang on Cost-effectiveness of Adjuvant Alectinib in ALK-positive NSCLC-Considerations for Broader Applicability. Lung cancer (Amsterdam, Netherlands), 213, 108944. https://doi.org/10.1016/j.lungcan.2026.108944

Chicago Style (17th ed.) Citation

R, Supiot, du Manoir de Juaye L, and Chouaid C. "Response to the Letter of Peng Bai and Jun Zhang on Cost-effectiveness of Adjuvant Alectinib in ALK-positive NSCLC-Considerations for Broader Applicability." Lung Cancer (Amsterdam, Netherlands) 213 (2026): 108944. https://doi.org/10.1016/j.lungcan.2026.108944.

MLA (9th ed.) Citation

R, Supiot, et al. "Response to the Letter of Peng Bai and Jun Zhang on Cost-effectiveness of Adjuvant Alectinib in ALK-positive NSCLC-Considerations for Broader Applicability." Lung Cancer (Amsterdam, Netherlands), vol. 213, 2026, p. 108944, https://doi.org/10.1016/j.lungcan.2026.108944.